by Marisa Wexler, MS | Jan 13, 2026 | Myeloma News
Johnson & Johnson is now seeking regulatory approval in the European Union for Tecvayli (teclistamab) plus Darzalex Faspro (daratumumab and hyaluronidase-fihj) for individuals with previously-treated multiple myeloma. The company has submitted an application to...
by Marisa Wexler, MS | Jan 12, 2026 | Myeloma News
All four adults with hard-to-treat acute myeloid leukemia (AML) who received treatment with a combination of Venclexta (venetoclax) and AB Science‘s experimental therapy AB8939 have responded to treatment, according to an update from AB. The company previously...
by MM360 Staff | Jan 10, 2026 | Myeloma News
Source: Myeloma : nature.com subject feeds Post Content Read More
by MM360 Staff | Jan 10, 2026 | Myeloma News
Source: Pharmacy Times articles Post Content Read More
by Marisa Wexler, MS | Jan 9, 2026 | Myeloma News
A new experimental treatment for pancreatic cancer, ARB1002, has been granted an orphan drug designation by the U.S. Food and Drug Administration (FDA) and is expected to enter early clinical testing later this year. The FDA reserves this status for treatments...
by MM360 Staff | Jan 9, 2026 | Myeloma News
Source: Myeloma : nature.com subject feeds Post Content Read More
